Epitalon (Epithalon; tetrapeptide Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the pineal gland peptide Epithalamin, studied by Russian researcher Vladimir Khavinson for telomerase activation and longevity applications[1]. No published human or animal pharmacokinetic study has formally characterized Epitalon's plasma half-life. Based on structural analog comparison with similar tetrapeptides, a half-life of approximately 30 minutes is estimated. Data quality: Animal Study + limited human observational data (low evidence) — no human PK study has been published as of May 2026.
| Parameter | Value | Source |
|---|---|---|
| Elimination Half-Life | ~30 minutes (estimated — no PK study) | Structural analog inference |
| Time to Peak (Tmax) | Not established | — |
| Route(s) of Administration | Subcutaneous injection, Intravenous, Intranasal | — |
| Plasma Protein Binding | Not published | — |
| Full Clearance (5 half-lives) | ~150 min est. (~2.5 hours) — not confirmed | Calculated from estimate |
| Standard Research Protocol | 5–10 mg/day SC for 10–20 day courses | Khavinson research protocols [1] |
| Approval Status | Not FDA-approved; not EMA-approved | — |
| Data Quality | Animal Study + limited human observational — no published human PK study as of May 2026 | — |
Epitalon's half-life has not been formally established in any published pharmacokinetic study. No peer-reviewed paper in English or Russian scientific literature has published a plasma concentration-time curve, elimination rate constant, or half-life value for Epitalon derived from dedicated pharmacokinetic measurements in humans or animals. The estimated half-life of approximately 30 minutes is inferred from structural analog comparison with similar short-chain tetrapeptides, which typically exhibit rapid plasma clearance due to susceptibility to serum peptidases and small molecular weight (enabling renal filtration)[1].
This is an honest and important disclosure. Many sources on the internet state Epitalon's half-life as approximately 30 minutes as if it were a measured value. It is not. It is an estimate. Halflife Labs distinguishes explicitly between measured pharmacokinetic values and inferred estimates — the "Data Quality: Inferred" classification on this page means no PK study has been conducted, not that the estimate is unreliable as a structural inference.
If a formal pharmacokinetic study were conducted for Epitalon, it would involve administering a known dose via subcutaneous or intravenous injection to human volunteers or animals, collecting serial blood samples, and measuring plasma Epitalon concentration over time using validated LC-MS/MS or immunoassay methods. The time required for plasma concentration to fall by 50% would be the half-life. No such study has been published in English-language peer-reviewed literature as of May 2026. Russian research groups, including Khavinson's Saint Petersburg Institute team, have published extensively on Epitalon's biological effects, but not on its pharmacokinetic profile[1].
The distinction between plasma half-life and biological effect duration is especially important for Epitalon because its proposed mechanism — telomerase activation leading to telomere elongation — is inherently a long-timescale biological process. Even if Epitalon's plasma half-life is approximately 30 minutes, the downstream biological effects of telomerase activation and epigenetic gene regulation would, if the mechanism is correct, persist for months to years after the peptide has cleared from plasma. This creates a fundamentally different relationship between PK half-life and clinical effect duration compared to most other research compounds[1].
Based on the estimated half-life of approximately 30 minutes (inferred from structural analogy), the following clearance timeline is a calculated estimate — not measured pharmacokinetic data:
| Half-Lives Elapsed | Estimated Time (Inferred) | % Remaining |
|---|---|---|
| 1 | ~30 minutes (estimated) | 50% |
| 2 | ~60 minutes (estimated) | 25% |
| 3 | ~90 minutes (estimated) | 12.5% |
| 4 | ~120 minutes (estimated) | 6.25% |
| 5 (clearance threshold) | ~150 minutes (~2.5 hours; estimated) | ~3% |
Epitalon is typically administered in structured courses — e.g., 5–10 mg subcutaneously once or twice daily for 10–20 consecutive days, repeated periodically (e.g., twice yearly). This course-based dosing strategy, derived from the Khavinson research protocols[1], reflects the hypothesis that Epitalon's mechanism operates through epigenetic and telomerase-mediated effects that persist long after plasma clearance. The dosing strategy is designed to deliver a sufficient cumulative stimulus to trigger persistent biological changes, not to maintain continuous plasma levels.
This is mechanistically different from compounds like GLP-1 agonists or testosterone esters, where ongoing plasma levels are required for continuous receptor occupancy and effect maintenance. Epitalon's putative mechanism predicts that periodic course dosing produces biological effects that outlast the dosing period by months — but this prediction is based on the Russian longevity research, which lacks prospective RCT validation to the standards required for regulatory approval.
| Compound | Half-Life | Data Quality | Proposed Mechanism |
|---|---|---|---|
| Epitalon | ~30 min (estimated) | Inferred — no PK study | Telomerase activation, pineal bioregulation |
| MOTS-C | Not established | Animal + early human obs. | AMPK activation, insulin sensitization |
| NAD+ Injectable | ~1–5 min (IV plasma) | Human PK Study (limited) | NAD+ repletion, sirtuin activation |
| GHK-Cu | Minutes (estimated) | Inferred | Wound repair, collagen synthesis |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | ~30 min (inferred) | Not published | Not published | Most common route in research protocols; used in Khavinson studies |
| Intravenous | Shorter than SC (inferred) | 100% | Minutes | Used in some research protocols; rapid clearance expected |
| Intranasal | No published data | No published data | No published data | Used by some researchers; CNS delivery hypothesis; no PK data |
| Oral | Not viable systemically | Negligible (peptide degradation) | — | GI proteolysis degrades the tetrapeptide before systemic absorption |
Epitalon is not included in standard WADA anti-doping panels or standard workplace drug tests. It is a research compound with no clinical approval in Western regulatory jurisdictions. Standard immunoassay panels target controlled substance classes and have no cross-reactivity with tetrapeptides like Epitalon.
No published forensic or anti-doping detection study has characterized the urinary detection window for Epitalon. Specialized LC-MS/MS methods could in principle detect small peptides in urine, but no published anti-doping method specifically targeting Epitalon has been identified in the literature as of May 2026. Given the estimated ~30-minute plasma half-life, urinary detection windows would likely be short.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) that was derived from the natural pineal gland peptide extract Epithalamin. The proposed primary mechanism is activation of telomerase (TERT — telomere reverse transcriptase), the enzyme responsible for adding telomeric DNA repeats to the ends of chromosomes. Shortened telomeres are associated with cellular senescence and aging; telomerase activation is hypothesized to slow or partially reverse this process[1].
Khavinson et al. (2003) published observations from Russian clinical studies reporting effects on longevity markers, immune function, and neuroendocrine regulation in older human subjects[1]. These studies constitute the primary human evidence base for Epitalon. They represent observational and clinical cohort research rather than randomized controlled trials with pharmacokinetic endpoints, and they were conducted primarily within the Russian research system without subsequent independent replication in Western clinical settings.
The proposed secondary mechanism involves pineal gland bioregulation: Epitalon may modulate melatonin synthesis and pineal function, which in turn influences circadian rhythms, immune regulation, and neuroendocrine aging processes. This dual mechanism hypothesis — telomerase activation plus pineal bioregulation — is based on the Epithalamin parent compound's observed effects on pineal function in Russian neuroendocrinology research.
The critical gap between the proposed mechanism and the available evidence is the absence of human pharmacokinetic data. Without knowing how much Epitalon reaches target tissues after subcutaneous injection, how long it persists in tissue, and whether it reaches the nucleus in concentrations sufficient to activate telomerase, the mechanistic chain from injection to telomere elongation cannot be confirmed. This is an honest characterization of the current state of the evidence.
Log your dosing course, injection timing, and protocol notes on-device. No account required. Free iOS app.
Download on App StoreThe Halflife app tracks Epitalon alongside 44 other compounds — all with citation-backed PK data. Free on iOS.
Download on the App Store